Neuberger Berman Group LLC cut its stake in shares of Qiagen NV (NYSE:QGEN) by 0.9% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,461,635 shares of the company’s stock after selling 12,654 shares during the period. Neuberger Berman Group LLC’s holdings in Qiagen were worth $59,459,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in QGEN. Oppenheimer Asset Management Inc. purchased a new position in Qiagen during the fourth quarter valued at $118,000. Rhumbline Advisers raised its stake in Qiagen by 3.0% during the fourth quarter. Rhumbline Advisers now owns 190,464 shares of the company’s stock valued at $6,561,000 after buying an additional 5,570 shares during the last quarter. BB&T Securities LLC raised its stake in shares of Qiagen by 7.0% in the fourth quarter. BB&T Securities LLC now owns 7,527 shares of the company’s stock worth $259,000 after purchasing an additional 490 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Qiagen by 11.6% in the fourth quarter. WINTON GROUP Ltd now owns 459,815 shares of the company’s stock worth $15,841,000 after purchasing an additional 47,819 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Qiagen by 9.2% in the fourth quarter. Cerity Partners LLC now owns 10,374 shares of the company’s stock worth $357,000 after purchasing an additional 877 shares during the last quarter. 63.22% of the stock is currently owned by hedge funds and other institutional investors.
Shares of QGEN traded up $0.22 during mid-day trading on Wednesday, reaching $39.22. 26,116 shares of the company’s stock traded hands, compared to its average volume of 1,299,756. Qiagen NV has a 12 month low of $32.33 and a 12 month high of $41.55. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 29.26, a P/E/G ratio of 2.34 and a beta of 0.84. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69.
Qiagen (NYSE:QGEN) last announced its earnings results on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The business had revenue of $348.70 million for the quarter, compared to analysts’ expectations of $351.68 million. During the same quarter last year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. As a group, analysts predict that Qiagen NV will post 1.43 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on QGEN shares. UBS Group began coverage on Qiagen in a research note on Friday, March 15th. They issued a “neutral” rating and a $42.00 price target for the company. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a report on Friday, April 12th. Goldman Sachs Group reissued a “buy” rating on shares of Qiagen in a report on Tuesday, May 7th. Finally, Wolfe Research assumed coverage on Qiagen in a report on Thursday, May 30th. They set a “peer perform” rating for the company. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $41.71.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/12/qiagen-nv-nyseqgen-shares-sold-by-neuberger-berman-group-llc.html.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: How do CD ladders protect against rising interest rates?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.